Chawalit Banpot/iStock via Getty Images Innate Pharma ( NASDAQ: IPHA ) is off 9% in Monday trading after releasing updated phase 1/2 data from the dose escalation portion of SAR443579/IPH6101 (SAR'579), which is being developed with Sanofi ( NASDAQ: SNY ), for various blood cancers. The study is looking at SAR'579 as monotherapy for acute myeloid leukemia, B‐cell acute lymphoblastic leukemia, and high-risk myelodysplasia. In the trial , 59 patients with a median of two prior lines of therapy received treatment across 11 dose levels.
The median treatment duration was 7.9 weeks, with durable complete response of more than 10 months seen in three patients. Also, five complete remissions were achieved at the 1 mg/kg dose.
SAR'579 is considered a CD123 targeting NKp46/CD16-based Natural Killer Cell Engager. More on Sanofi, Innate Pharma Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Innate Pharma: Worth A Deeper Look Regeneron, Sanofi win FDA label expansion for arthritis therapy Kevzara Innate Pharma S.A.
(IPHA) Q1 2024 Earnings Call Transcript.